Sugi Predict

Sugi Predict / Targets / PHGDH

PHGDH

D-3-phosphoglycerate dehydrogenase · O43175 · PHGDH on Sugi Atlas →

29,095 patent compounds predicted against PHGDH, 16,564 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL663937 SCHEMBL663937 0.71 12/20
SCHEMBL663017 SCHEMBL663017 0.66 12/20
SCHEMBL881424 SCHEMBL881424 0.51 10/20
SCHEMBL881498 SCHEMBL881498 0.52 9/20
SCHEMBL881204 SCHEMBL881204 0.50 9/20
SCHEMBL42264 SCHEMBL42264 0.43 9/20
SCHEMBL47199 SCHEMBL47199 0.43 9/20
SCHEMBL881501 SCHEMBL881501 0.50 8/20
SCHEMBL22910 SCHEMBL22910 0.80 7/20
Bis(Piperidinylthiocarbonyl)Disulfide Bis(Piperidinylthiocarbonyl)Disulfide (SCHEMBL139465) 1.00 6/20
SCHEMBL43328 SCHEMBL43328 0.59 6/20
SCHEMBL417998 SCHEMBL417998 0.49 6/20
SCHEMBL881499 SCHEMBL881499 0.49 6/20
SCHEMBL881187 SCHEMBL881187 0.48 6/20
SCHEMBL718533 SCHEMBL718533 0.46 6/20
SCHEMBL881500 SCHEMBL881500 0.41 6/20
SCHEMBL353275 SCHEMBL353275 0.39 6/20
SCHEMBL650389 SCHEMBL650389 0.32 6/20
SCHEMBL650390 SCHEMBL650390 0.32 6/20
SCHEMBL651241 SCHEMBL651241 0.32 6/20

Clinical trials — most relevant to PHGDH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Bioenergetic Effect of Pioglitazone in CLD-PH PHASE2RECRUITING
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) PHASE2RECRUITING
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer PHASE2SUSPENDED
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy PHASE2SUSPENDED
Erythropoietin Therapy for Subarachnoid Hemorrhage PHASE2COMPLETED
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer PHASE2COMPLETED
Anaplerotic Therapy in Propionic Acidemia PHASE1COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment nanUNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors nanUNKNOWN
Clinical Study on the Expression of PHGDH and Its Prognostic Value in Colorectal Cancer Patients Receiving Immunotherapy nanCOMPLETED
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies nanRECRUITING
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH) nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Genetic and Metabolic Disease in Children nanRECRUITING
GSD VI and GSD IX Natural History nanRECRUITING
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia nanCOMPLETED
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma nanNOT_YET_RECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma nanUNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PHGDH binder may also engage these)

ProteinNameSimilarity
A5GFY8 — 1.000 A5GFY8 →
Q60HD7 — 1.000 Q60HD7 →
Q61753 — 1.000 Q61753 →
Q5EAD2 — 1.000 Q5EAD2 →
Q5R7M2 — 1.000 Q5R7M2 →
O08651 — 1.000 O08651 →
A5A6P1 — 1.000 A5A6P1 →
Q8AWD2 — 0.976 Q8AWD2 →
Q5RC31 — 0.975 Q5RC31 →
P37142 — 0.974 P37142 →
Q29554 — 0.974 Q29554 →
A8E657 — 0.974 A8E657 →
Q9UDR5 — 0.974 Q9UDR5 →
Q9DCM0 — 0.973 Q9DCM0 →
Q58H57 — 0.973 Q58H57 →
Q9CZ42 — 0.973 Q9CZ42 →
P49079 — 0.973 P49079 →
O04130 — 0.973 O04130 →
Q9LT69 — 0.973 Q9LT69 →
Q64428 — 0.973 Q64428 →
Q9GZT8 — 0.972 Q9GZT8 →
Q91Z53 — 0.972 Q91Z53 →
Q59A32 — 0.972 Q59A32 →
Q99LC5 — 0.972 Q99LC5 →
P49080 — 0.972 P49080 →
Q9SXP2 — 0.972 Q9SXP2 →
P54887 — 0.972 P54887 →
Q9V6U8 — 0.972 Q9V6U8 →
O95396 — 0.971 O95396 →
Q64737 — 0.971 Q64737 →